Uncovered versus fully-covered self-expandable metal stents for nonpancreatic cancer: Propensity score-matched, multicenter study

非胰腺癌患者使用裸金属支架与全覆膜自膨式金属支架的比较:倾向评分匹配的多中心研究

阅读:1

Abstract

BACKGROUND AND STUDY AIMS: The efficacy of uncovered self-expandable metal stents (UCSEMS) compared to that of fully covered self-expandable metal stents (FCSEMS) for distal malignant biliary obstruction (dMBO) is controversial. Studies have highlighted the heterogeneity of disease conditions because pancreatic and nonpancreatic cancers exhibit different clinical courses. This is the first study to specifically compare the safety and efficacy of UCSEMS and FCSEMS for dMBO caused by nonpancreatic cancer. PATIENTS AND METHODS: This retrospective multicenter study included patients who underwent UCSEMS or FCSEMS placement for nonpancreatic cancer-induced dMBO at four centers between January 2010 and April 2024. Propensity score matching (PSM) (1:1) of both groups was performed. Technical and clinical success, adverse events, recurrent biliary obstruction (RBO), time to RBO (TRBO), and overall survival (OS) of these groups were compared. RESULTS: After PSM, 24 patients were included in each group. Technical and clinical success rates and TRBO did not differ significantly between the groups (median TRBO: 311 days [UCSEMS] vs 317 days [FCSEMS]; P = 0.42). Similarly, OS was not significantly different (median OS: 432 days [UCSEMS] vs 190 days [FCSEMS]; P = 0.083). Incidence of pancreatitis after endoscopic retrograde cholangiopancreatography in the UCSEMS group was significantly lower than that in the FCSEMS group (4.2% vs. 33%; P = 0.023). CONCLUSIONS: UCSEMS may be safer than FCSEMS for managing dMBO caused by nonpancreatic cancer.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。